SCHEMBL9931300

SCHEMBL9931300

N#Cc1ccc(C(F)F)c(Br)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
TTR P02766 1/20 0.42
ALB P02768 1/20 0.42
KMT2A Q03164 1/20 0.42
HTT P42858 1/20 0.36
PNMT P11086 1/20 0.35
PTPN1 P18031 2/20 0.35
PTPN2 P17706 1/20 0.35
EGLN2 Q96KS0 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
CYP11B2 P19099 1/20 0.33
CXCR1 P25024 1/20 0.33
CXCR2 P25025 1/20 0.33
GSK3B P49841 2/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
CYP2A6 P11509 2/20 0.32
IMPDH2 P12268 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19995400 0.84 MEN1 (0.38) MEN1TTRALBKMT2AHTT
SCHEMBL29865001 0.82 MEN1 (0.43) MEN1TTRALBKMT2AHTT
SCHEMBL9931297 0.82 MEN1 (0.43) MEN1TTRALBKMT2AHTT
SCHEMBL4419556 0.80 PTPN1 (0.49) MEN1TTRALBKMT2APNMT
SCHEMBL12251119 0.80 MEN1 (0.42) MEN1TTRALBKMT2AHTT
SCHEMBL28794938 0.78 MEN1 (0.41) MEN1TTRALBKMT2AHTT
SCHEMBL8576534 0.78 KIF11 (0.37) MEN1KMT2APNMTEGLN2CYP11B2
SCHEMBL6796667 0.77 MEN1 (0.44) MEN1TTRALBKMT2AHTT
SCHEMBL8573289 0.76 VCAM1 (0.41) PNMTEGLN2MAOAMAOBCYP11B2
SCHEMBL30876218 0.75 GRIN2B (0.39) PNMTEGLN2CYP2A6IMPDH2IMPDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027113-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS INC (US) 2026-01-29 US disclosed
US-12465603-B2 Phthalazinone based modulators for the treatment of disease SOLEY THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
EP-4619387-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2025-09-24 EP disclosed
US-20240374589-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. 2024-11-14 US disclosed
WO-2024108131-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed
US-8648200-B2 Imidazole derivatives useful for the treatment of arthritis ELI LILLY AND COMPANY (US) 2014-02-11 US disclosed
EP-2655335-A1 NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS Eli Lilly and Company (US) 2013-10-30 EP disclosed
US-20120302608-A1 Novel Imidazole Derivatives Useful for the Treatment of Arthritis ELI LILLY AND COMPANY (US) 2012-11-29 US disclosed
WO-2012161965-A1 NOVEL IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF ARTHRITIS ELI LILLY AND COMPANY (US) 2012-11-29 WO disclosed
US-8252831-B2 Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis ELI LILLY AND COMPANY (US) 2012-08-28 US disclosed
WO-2012087771-A1 NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS ELI LILLY AND COMPANY (US) 2012-06-28 WO disclosed
US-20120157506-A1 Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis ELI LILLY AND COMPANY (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302608-A1 Novel Imidazole Derivatives Useful for the Treatment of Arthritis F12, IL1RN, ARG1 MEN1 3664/4885TTR 1989/4885ALB 3457/4885
US-12465603-B2 Phthalazinone based modulators for the treatment of disease MKI67, BCL2, CCAR2 MEN1 1555/4885TTR 3982/4885ALB 4493/4885
US-20260027113-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE NCOR1, NOP56, NCOR2 MEN1 2848/4885TTR 3135/4885ALB 3875/4885
US-20120157506-A1 Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis ARG2, HDAC6, COL2A1 MEN1 2800/4885TTR 2126/4885ALB 3981/4885
US-20240374589-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE MKI67, HDAC6, BCL2 MEN1 1629/4885TTR 2946/4885ALB 4103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.